Ascendis Pharma A/S (NASDAQ:ASND) Upgraded by Citigroup to “Strong-Buy” Rating

Citigroup upgraded shares of Ascendis Pharma A/S (NASDAQ:ASND) to a strong-buy rating in a report published on Monday,Zacks.com reports.

A number of other brokerages also recently commented on ASND. Wells Fargo & Company lowered their price target on shares of Ascendis Pharma A/S from $330.00 to $326.00 and set an “overweight” rating for the company in a report on Friday, May 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Ascendis Pharma A/S in a report on Wednesday, January 21st. Royal Bank Of Canada increased their price target on shares of Ascendis Pharma A/S from $250.00 to $275.00 and gave the company an “outperform” rating in a report on Monday, March 2nd. Stifel Nicolaus set a $332.00 price target on shares of Ascendis Pharma A/S in a report on Wednesday, March 4th. Finally, The Goldman Sachs Group reaffirmed a “buy” rating and issued a $255.00 price target on shares of Ascendis Pharma A/S in a report on Monday, March 2nd. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $295.39.

Ascendis Pharma A/S Stock Up 0.1%

Shares of NASDAQ:ASND opened at $237.96 on Monday. The company has a current ratio of 1.00, a quick ratio of 0.72 and a debt-to-equity ratio of 0.79. Ascendis Pharma A/S has a 12 month low of $153.49 and a 12 month high of $250.74. The company has a 50-day moving average price of $232.12 and a 200 day moving average price of $221.06. The company has a market cap of $14.84 billion, a price-to-earnings ratio of 27.45 and a beta of 0.41.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings results on Thursday, May 7th. The biotechnology company reported $0.32 EPS for the quarter, beating analysts’ consensus estimates of $0.21 by $0.11. The business had revenue of $285.45 million during the quarter, compared to the consensus estimate of $362.47 million. As a group, equities research analysts predict that Ascendis Pharma A/S will post 12.19 earnings per share for the current year.

Insider Transactions at Ascendis Pharma A/S

In other Ascendis Pharma A/S news, insider Flemming Steen Jensen sold 19,460 shares of the firm’s stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $238.49, for a total value of $4,641,015.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 40.00% of the stock is currently owned by insiders.

Institutional Trading of Ascendis Pharma A/S

Several institutional investors have recently added to or reduced their stakes in the company. Rhumbline Advisers raised its stake in shares of Ascendis Pharma A/S by 4.0% during the second quarter. Rhumbline Advisers now owns 1,441 shares of the biotechnology company’s stock valued at $249,000 after acquiring an additional 55 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Ascendis Pharma A/S by 1.0% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,081 shares of the biotechnology company’s stock valued at $1,209,000 after acquiring an additional 58 shares in the last quarter. Certuity LLC raised its stake in shares of Ascendis Pharma A/S by 5.7% during the fourth quarter. Certuity LLC now owns 1,170 shares of the biotechnology company’s stock valued at $249,000 after acquiring an additional 63 shares in the last quarter. Personal CFO Solutions LLC raised its stake in shares of Ascendis Pharma A/S by 4.4% during the first quarter. Personal CFO Solutions LLC now owns 1,519 shares of the biotechnology company’s stock valued at $347,000 after acquiring an additional 64 shares in the last quarter. Finally, EverSource Wealth Advisors LLC raised its stake in shares of Ascendis Pharma A/S by 34.0% during the first quarter. EverSource Wealth Advisors LLC now owns 272 shares of the biotechnology company’s stock valued at $62,000 after acquiring an additional 69 shares in the last quarter.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.